Implementing a national cancer clinical trials system for the 21st century
Subtitle: workshop summary
By: an American Society of Clinical Oncology and Institute of Medicine Workshop ; Alison Mack and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies
Contributors: Mack, Alison; Nass, Sharyl J.; American Society of Clinical Oncology; Institute of Medicine (U.S.). Board on Health Care Services; National Cancer Policy Forum (U.S.)
Publisher: National Academies Press
Published: 2011
Place of publication: Washington, D.C
Language: eng
Number of pages: 108
ISBN-13: 9780309212687
Subjects: Government policy; Clinical trials; Cancer; Congresses; Treatment; American Society of Clinical Oncology; Standards
Description: "Clinical trials enable scientific discoveries to advance patient care, in addition to informing and guiding subsequent research. The National Cancer Institute's (NCI's) Clinical Trials Cooperative Group Program works to advance patient care and research. The Cooperative Group Program has been instrumental in establishing the standards for cancer patient care and clinical research methods. Despite broad participation in the program, financial strain and procedural burdens limit the ability of the Cooperative Group Program to undertake medical practice-changing clinical research. Thus, the Institute of Medicine's (IOM's) National Cancer Policy Forum and the American Society of Clinical Oncology held a workshop on March 21, 2011 to follow up on the 2010 IOM report, A National Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, which made recommendations to strengthen the NCI Cooperative Group Program. In keeping with the established commitment to excellence Implementing a National Cancer Clinical Trials System for the 21st Century outlines how to improve the current system by incorporating innovative science and trial design into cancer clinical trials. It also examines the impact of increasing quality in regards to speed, efficiency, design, launch, and conduct, as well as improving prioritization, and incentivized participation."--Publisher's description.
Notes: Includes bibliographical references (p. 91-93).

Also available online.
Table of contents: title: Panel I : NCI and the cooperative groups; title: Panel II : Payors; title: Panel III : Interactions between industry, the FDA, and the publicly funded cancer clinical trials system; title: Panel IV : Clinical trials investigators and patient advocates.